Vical Joins Forces With Astellas On CMV Vaccine
This article was originally published in The Pink Sheet Daily
Executive Summary
Astellas will take over the development of TransVax and pay Vical $103 million plus royalties.
You may also be interested in...
Vical Shifts To Infectious Disease After Allovectin Fails In Melanoma
CEO Vijay Samant defends Vical’s DNA-based technology platform after 20 years of development culminates in Phase III failure. But the platform still shows promise in other therapeutic areas, Vical says as the company absorbs a major blow to stock price.
Cash-Strong Vical Narrows Focus To Two Lead Programs
Wary of current financial environment, biotech is bullish on early pipeline projects but will await partners to advance them.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.